Akeso's ebdarokimab approved in China for psoriasis treatment

Akeso, Inc. announced that the NMPA has approved its NDA for Ebdarokimab, an IL-12/IL-23 antibody, for treating moderate to severe plaque psoriasis. Ebdarokimab is Akeso's first Class 1 new drug for autoimmune diseases and the second non-oncology new drug to obtain marketing approval. Clinical trials showed a 79.4% PASI 75 response rate at week 16 for patients receiving ebdarokimab, with a maintained 77.9% PASI 75 response rate at week 52 with maintenance therapy. The drug's administration involves four annual subcutaneous injections. Ebdarokimab is the first and only commercialized IL-12/IL-23 monoclonal antibody in China.